CDK1 and autosomal dominant polycystic kidney disease: To explore this prediction experimentally, we screened mebendazole against a kinase panel enriched with targets predicted or known to be inhibited by mebendazole, or important in ADPKD, and determined that in addition to the predictions VEGFR2 and Abl, mebendazole also inhibited VEGFR1, Met and CDK1, which have all been implicated in ADPKD.